US Patent Issued to Biocytogen Pharmaceuticals (Beijing) on Sept. 22 for "Genetically modified non-human animal with human or chimeric TFR1" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,740,550, issued on Sept. 22, was assigned to Biocytogen Pharmaceuticals (Beijing) Co. Ltd. (Beijing).

"Genetically modified non-human animal with human or chimeric TFR1" was invented by Chang Liu (Beijing), Chengzhang Shang (Beijing) and Xiaofei Zhou (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) TFR1, and methods of use thereof."

The patent was filed on July 15, 2022, under Application No. 18/566,898.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITO...